It’s been something of a staple product in the beauty industry for years, but recent developments have redefined its use and could be changing the way it’s delivered to clinics - a powder ready to be salinated according to the physician’s parameters
BOTOX GETS A NEW LOOK
THERE ARE TWO THINGS NOT WIDELY KNOWN OUTSIDE THE INDUSTRY ABOUT BOTOX: IT’S USE AS A COSMETIC enhancement was discovered almost by chance and it’s mixed in powder form. The first dates back to the late eighties when, under its original name of Oculinum, it was used to treat the eye condition, Strabismus – or misalignment of the eyes - in children. It was only when a physician in New York went a step further and used it to treat under-eye muscle spasms that he noticed the furrow lines of the brow had begun to soften. His patient, aware of their “crow’s feet”, noticed it too and asked that he treated the other eye as well. Until then it had only ever been used as a medical, rather than aesthetic, compound. And until now, it had only ever been supplied in powder form and the saline dilution was something left to individual practitioners But all that could begin to change now that the Swiss pharmaceutical company, Galderma, has confirmed the first ready-to-use liquid neuromodulator has completed its European decentralised trial. Unlike other botulinum toxin products on the market, Alluzience®
does not need reconstitution before use, something the company claims will enable healthcare professionals to avoid complex calculations, allowing for more precision, optimised results and higher patient satisfaction. Alexandre Brennan, head of the global business unit at Galderma, described the news as an
“important milestone” for both patients and healthcare professionals, adding: “We pride ourselves on developing innovative products that meet today’s needs. We know how advantageous it is for practitioners to have access to a ready-to-use liquid formulation.” Botox®
is the trade name of Allergan’s purified protein
botulinum toxin Type A, which is derived from the anaerobic bacterium Clostridium botulinum. It has been approved in more than 75 countries to treat 20 different neurological disorders. As well as its cosmetic application, it has been used for a range of therapeutic applications, including excessive sweating.
THE DETAIL IS IN THE DATA According to Galderma, Alluzience®
is intended for use in
adult patients to temporarily improve the appearance of moderate to severe glabellar lines. The European Marketing Authorisation Application of Alluzience®
from two trials of 372 patients with moderate to severe lines who were treated with either Alluzience®
placebo. The data showed that less than 50 per cent of patients reported an effect within two to three days, including 23 per cent of patients within one day. An effect was demonstrated for up to six months after injection with Alluzience®
. The responder rate at day 29 was higher for patients treated with
supplied data or
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61
